JP2020510426A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510426A5
JP2020510426A5 JP2019546855A JP2019546855A JP2020510426A5 JP 2020510426 A5 JP2020510426 A5 JP 2020510426A5 JP 2019546855 A JP2019546855 A JP 2019546855A JP 2019546855 A JP2019546855 A JP 2019546855A JP 2020510426 A5 JP2020510426 A5 JP 2020510426A5
Authority
JP
Japan
Prior art keywords
rna
region
protein
mrna
coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019546855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510426A (ja
JP7674077B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020018 external-priority patent/WO2018160592A1/en
Publication of JP2020510426A publication Critical patent/JP2020510426A/ja
Publication of JP2020510426A5 publication Critical patent/JP2020510426A5/ja
Priority to JP2022209557A priority Critical patent/JP2023052106A/ja
Application granted granted Critical
Publication of JP7674077B2 publication Critical patent/JP7674077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019546855A 2017-02-28 2018-02-27 翻訳可能分子およびその合成 Active JP7674077B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022209557A JP2023052106A (ja) 2017-02-28 2022-12-27 翻訳可能分子およびその合成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762465073P 2017-02-28 2017-02-28
US62/465,073 2017-02-28
PCT/US2018/020018 WO2018160592A1 (en) 2017-02-28 2018-02-27 Translatable molecules and synthesis thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209557A Division JP2023052106A (ja) 2017-02-28 2022-12-27 翻訳可能分子およびその合成

Publications (3)

Publication Number Publication Date
JP2020510426A JP2020510426A (ja) 2020-04-09
JP2020510426A5 true JP2020510426A5 (OSRAM) 2021-04-15
JP7674077B2 JP7674077B2 (ja) 2025-05-09

Family

ID=63370513

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019546855A Active JP7674077B2 (ja) 2017-02-28 2018-02-27 翻訳可能分子およびその合成
JP2022209557A Pending JP2023052106A (ja) 2017-02-28 2022-12-27 翻訳可能分子およびその合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022209557A Pending JP2023052106A (ja) 2017-02-28 2022-12-27 翻訳可能分子およびその合成

Country Status (4)

Country Link
US (2) US11407800B2 (OSRAM)
EP (1) EP3589290A4 (OSRAM)
JP (2) JP7674077B2 (OSRAM)
WO (1) WO2018160592A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3589290A4 (en) 2017-02-28 2020-12-30 Arcturus Therapeutics, Inc. Translatable molecules and synthesis thereof
US11685906B2 (en) 2018-12-06 2023-06-27 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
CN110331147A (zh) * 2019-06-21 2019-10-15 苏州吉玛基因股份有限公司 一种mRNA的制备方法及其在肿瘤治疗中的应用
CA3169889A1 (en) 2020-03-03 2021-09-10 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
US11759515B2 (en) 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
WO2021222801A2 (en) 2020-05-01 2021-11-04 Arcturus Therapeutics, Inc. Nucleic acids and methods of treatment for cystic fibrosis
WO2022036170A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CA3128660A1 (en) * 2020-10-09 2022-04-09 Eric G. Marcusson Compositions and methods for the prevention and/or treatment of covid-19
CN113372432A (zh) * 2021-06-15 2021-09-10 深圳市臻质医疗科技有限公司 一种基于化学修饰mRNA编码蛋白因子诱导和/或增强软骨损伤修复的方法
AU2023274159A1 (en) * 2022-09-07 2024-03-21 Eyegene Inc. COMPOSITION FOR IN-VIVO DELIVERING mRNA CONTAINING MODIFIED NUCLEOTIDE
KR102785258B1 (ko) * 2022-09-07 2025-03-26 아이진 주식회사 변형핵산 함유 mRNA의 체내 전달용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1857122E (pt) 2001-06-05 2011-03-07 Curevac Gmbh Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral
CN1318586C (zh) 2001-11-05 2007-05-30 詹森药业有限公司 短的双链RNAs的体外合成方法
ES2937245T3 (es) 2005-08-23 2023-03-27 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
US8304529B2 (en) 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US20090226906A1 (en) * 2008-03-05 2009-09-10 Helicos Biosciences Corporation Methods and compositions for reducing nucleotide impurities
HRP20220250T1 (hr) * 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
US9283287B2 (en) * 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
KR102315098B1 (ko) * 2012-11-01 2021-10-21 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
SMT202200337T1 (it) * 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP3212793B1 (en) * 2014-11-02 2020-01-08 Arcturus Therapeutics, Inc. Messenger una molecules and uses thereof
EP3461904A1 (en) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
EP3218508A4 (en) * 2014-11-10 2018-04-18 Modernatx, Inc. Multiparametric nucleic acid optimization
US20190382774A1 (en) * 2016-05-18 2019-12-19 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
EP3589290A4 (en) 2017-02-28 2020-12-30 Arcturus Therapeutics, Inc. Translatable molecules and synthesis thereof

Similar Documents

Publication Publication Date Title
JP2020510426A5 (OSRAM)
Tusup et al. Design of in vitro transcribed mRNA vectors for research and therapy
JP2010530245A5 (OSRAM)
AU2017226199A1 (en) Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
JP2008056679A5 (OSRAM)
WO2013018778A1 (ja) ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
CN106459997A (zh) 用于疫苗应用的高效价病毒样囊泡的进化
JP2004501646A5 (OSRAM)
WO2023227124A1 (zh) 一种构建mRNA体外转录模板的骨架
WO2023035372A1 (zh) 一种有限自我复制mRNA分子系统、制备方法及应用
WO2018212361A1 (en) Method of treating diseases associated with myd88 pathways using crispr-gndm system
CN115485379A (zh) 用于体外mRNA转录的合成DNA模板
JP2025114633A (ja) インビトロトランスクリプトｍｒｎａ及びこれを含有する薬学組成物
EP3158060B1 (en) Method for rapid generation of an infectious rna virus
CN120641560A (zh) Rna聚合酶变体及其应用
JP2025520106A (ja) Ｍｒｎａの細胞内安定性と生合成を向上させるｕｔｒ配列を含む構成物とその使用
WO2024209218A1 (en) Coronavirus vaccines inducing broad immunity against variants
WO2023208118A9 (zh) 核酸构建体及其应用
CN110577972B (zh) CRISPR/Sa-ShaCas9基因编辑系统及其应用
JP2024509146A (ja) コロナウイルスに対して保護するためのワクチン産生のための完全合成長鎖核酸
Saini et al. High-level synthesis of Johnson grass mosaic virus coat protein in Escherichia coli and its auto-assembly to form virus-like particles
CN112725378A (zh) 一种人工改造的akt3环状rna及其在新冠疫苗中的应用
CN107759673B (zh) 可对hbv的dna进行表观甲基化修饰的蛋白分子及其应用
JP2006501166A5 (OSRAM)
Plotnikova et al. PRODUCTION AND BIOLOGICAL ACTIVITY OF THE EXOGENOUS mRNA ENCODING HUMAN MxA PROTEIN